Skip to main content
. 2017 Dec 1;8(70):114698–114709. doi: 10.18632/oncotarget.22815

Figure 8. The graphs correspond to the measurement of bioluminescence in Nod.Cg-PrkdcscidII2rgtm-Gammanull mice treated with VER155008 (40 mg/kg) or bortezomib (1 mg/kg), alone or in combination, for one week.

Figure 8

(A) BLI analysis of PrkdcscidII2rgtm-Gammanull mice related to RPMI8226-LUC-PURO cells xenograft (n = 3). Mice treated with VER155008 (40 mg/kg) or treated with bortezomib (1 mg/kg) plus VER155008 showed reduction in bioluminescence comparing to control group (p < 0.001), while treatment with bortezomib showed reduction in bioluminescence only after seven days of evaluation (p < 0.05). (B) BLI analysis of PrkdcscidII2rgtm-Gammanull mice related to U266-LUC-PURO cells xenograft (n = 3). Mice treated with VER155008 (40 mg/kg) or treated with bortezomib (1 mg/kg) plus VER155008 showed reduction in bioluminescence comparing to control group (p < 0.001), while treatment with bortezomib showed reduction in bioluminescence only after seven days of evaluation (p < 0.05).